Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition  by Yamanouchi, Dai et al.
Hydrophilic statin suppresses vein graft intimal
hyperplasia via endothelial cell-tropic Rho-kinase
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Background: Recent studies suggest that statins can protect the vasculature in a manner that is independent of their
lipid-lowering activity through inhibition of the small guanosine triphosphate-binding protein, Rho, and Rho-associated
kinase. Little information is available on the inhibitory effect of statins on vein graft intimal hyperplasia, the main cause
of late graft failure after bypass grafting. We therefore examined the effects of a hydrophilic statin on vein graft intimal
hyperplasia in vivo and Rho-kinase activity in vitro.
Methods: In the first experiment, rabbits were randomized to a control group (n  7) that was fed regular rabbit chow or
to a pravastatin group (n  7) that was fed regular rabbit chow supplemented with 10 mg/kg pravastatin sodium. The
branches of the jugular vein were ligated and an approximately 3-cm segment of the jugular vein was taken for an
autologous reversed-vein graft. The carotid artery was cut and replaced with the harvested autologous jugular vein.
At 2 and 4 weeks after the operation, vein grafts in both groups were harvested, and intimal hyperplasia of the vein grafts
was assessed. In the second experiment, human umbilical vein endothelial cells and vascular smooth muscle cells were
cultured and then treated with 1 mol/L and 30 mol/L pravastatin for 24 hours and harvested. Immunoblotting was
performed on the resulting precipitates. Quantitative evaluation of phosphorylated myosin binding subunit and
endothelial nitric oxide synthase was performed by densitometric analysis.
Results:We demonstrated that oral administration of the hydrophilic statin pravastatin to normocholesterolemic rabbits
inhibited intimal hyperplasia of carotid interposition-reversed jugular vein grafts 4 weeks after implantation (pravastatin
group, 39.5  3.5 m vs control group, 64.0  7.1 m; n  7; P < .05) and suppressed cell proliferation and apoptosis
in the neointima 2 weeks after implantation. In addition, we found that pravastatin inhibited Rho-kinase activity and
accelerated endothelial nitric oxide synthase expression in human umbilical vein endothelial cells but did not inhibit
Rho-kinase activity in vascular smooth muscle cells.
Conclusions:These novel findings clearly demonstrate that a hydrophilic statin can suppress intimal hyperplasia of the vein
graft in vivo and also show endothelial cell-tropic inhibition of Rho-kinase in vitro. Furthermore, these results strongly
support the clinical use of hydrophilic statins to prevent intimal hyperplasia of the vein graft after bypass grafting. (J Vasc
Surg 2005;42:757-64.)
Clinical Relevance: Late graft failure caused by neointimal hyperplasia limits the efficacy of vein grafting. Various
treatments were examined to reduce neointimal hyperplasia, but a standard clinical treatment has not yet been
established. We report here the inhibitory effect of pravastatin on the development of vein graft intimal hyperplasia. In
addition, we demonstrate that pravastatin showed endothelial cell-tropic benefits through both the inhibition of
Rho-kinase activity and acceleration of eNOS expression in vitro. Because the clinical benefits and safety of pravastatin
have been established to a certain extent through long-term clinical usage, pravastatin may soon become standard
treatment after vein bypass grafting.Arterial occlusive disease such as peripheral arterial
occlusive disease and coronary artery disease is a clinical
manifestation of atherosclerosis that is prevalent in indus-
trialized societies. An autologous vein graft is the most
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rial occlusive disease and coronary artery bypass grafting.1
However, late graft failure caused by either intimal hyper-
plasia or a progression of the underlying atherosclerotic
disease limits the efficacy of vein grafting.2,3
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG
CoA) reductase inhibitors, also known as statins, block the
rate-limiting step in cholesterol biosynthesis and are widely
prescribed to lower cholesterol synthesis in hyperlipidemic
patients.4 Several large clinical trials have demonstrated the
benefits of cholesterol lowering with these agents in the
primary and secondary prevention of coronary heart dis-
ease.5,6 Furthermore, subgroup analysis of the data from
clinical trials suggests that statins may have some beneficial
effects independent of their cholesterol-lowering effects.6,7
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cholesterol-independent (pleiotropic) effects of statins in-
volve suppression of cell proliferation8 and improvement or
restoration of endothelial function through endothelial
nitric oxide synthase (eNOS) activation.9 These effects may
reflect the ability of statins to block the synthesis of impor-
tant isoprenoid intermediates like the small guanosine
triphosphate (GTPase) protein, Rho, and Rho-
associated kinase (Rho-kinase/ROK/ROCK) activity.4,10
Our previous work demonstrated a relationship be-
tween NO and intimal hyperplasia of vein grafts.11-13
Other studies showed that long-term inhibition of Rho
kinase reversed endothelium-dependent relaxation and
caused regression of arterial intimal hyperplasia.14 How-
ever, there is no information regarding the effects of statins
on vein graft intimal hyperplasia.
Experimental studies indicate that some statins, but not
pravastatin, inhibited intimal hyperplasia in balloon-injured
arteries.15,16 However, some studies reported that the clin-
ical prescription of lipophilic statins was limited because
lipophilic statins showed more side effects and drug inter-
actions with cytochrome P450 (CYP) enzymes.17
The present study was therefore designed to determine
if oral administration of the hydrophilic statin pravastatin
suppresses intimal hyperplasia of the vein graft in vivo and,
if so, to confirm the previously reported effects of pravasta-
tin on cell proliferation and apoptosis.12 To elucidate the
vasculo-protective properties of a hydrophilic statin, we
also examined the effect of pravastatin on Rho-kinase activ-
ity and eNOS expression in different types of extrahepatic
cells in vitro.
METHODS
Experiment 1: In vivo effect of hydrophilic statin on
vein graft intimal hyperplasia
Animals and chemicals. Pravastatin sodium was ob-
tained from Sankyo Co, Ltd (Tokyo, Japan). Male Japanese
white rabbits (Nippon SLC, Hamamatsu, Japan), each
weighting 2.5 to 3.0 kg, were used in this study. The
rabbits were housed individually at 20°C  3°C with free
access to water. The animal experiments were fully re-
viewed by the Committee of Ethics on Animal Experiments
from the Faculty of Medicine, Nagoya University and were
carried out under the Guidelines for Animal Experiments in
the Faculty of Medicine, Nagoya University. The study also
was in conformance with the publication Guiding Princi-
ples for the Care andUse of Laboratory Animals (publication
No. NIH 80-23, revised 1985).
Drug administration. Rabbits were randomly di-
vided into a control group (n 7) that was fed commercial
rabbit chow (CR3) (CLEA Japan Inc, Tokyo, Japan) and a
pravastatin group (n  7) that received CR3 with 10-
mg/kg pravastatin sodium, as described in previous re-
ports.15,16 Feeding was restricted to 120 g/day. Pravastatin
treatment was started on the day of operation and contin-
ued until the end of the experiment. All the rabbits ap-
peared to be healthy throughout the course of study.Plasma lipid analysis. After an overnight fast, blood
samples were obtained in each group from the marginal ear
vein at the time of operation and 28 days after operation,
and plasma was obtained by the addition of sodium-
ethylenediamine tetraacetic acid . Total cholesterol, triglyc-
erides, and low-density lipoprotein (LDL) in plasma were
measured by enzymatic assays as previously reported.18
Vein graft implantation. Carotid interposition-reversed
jugular vein grafts were performed as described previously.12
Anesthesia was induced intramuscularly with ketamine hy-
drochloride (50 mg/kg) and xyradine (10 mg/kg) and
maintained with the intravenous administration of ket-
amine hydrochloride (10 mg/kg) and xyradine (10 mg/
kg). After a longitudinal neck incision, the left jugular vein
and the left common carotid artery were exposed. The
branches of the jugular vein were ligated and an approxi-
mately 3-cm segment of the jugular vein was taken for the
autologous reversed-vein graft. Graft harvesting was com-
pleted with meticulous care to avoid injuring the graft wall.
The harvested graft was kept moistened in heparinized
saline (5 IU/mL) at room temperature.
The carotid artery was clamped at the proximal and the
distal ends. The carotid artery was cut and replaced with the
harvested autologous jugular vein. The vein graft was anas-
tomosed in a reversed end-to-end fashion with interrupted
8-0 monofilament sutures under a surgical microscope.
The wound was closed layer to layer.
Harvest of implanted grafts. At each time point
after implantation of the autologous vein grafts, the vein
grafts were harvested under general anesthesia as de-
scribed previously.12 In brief, the graft was isolated and
harvested after systemic heparinization (200 IU/kg in-
travenously), and the rabbits were sacrificed by an over-
dose of pentobarbital. The harvested vein graft was fixed
with 4% formaldehyde at a pressure of 100 mmHg for 30
minutes. The perfused vein graft was immersed in the
same fixative overnight at room temperature. The middle
portion of the harvested graft was used for histologic
study and immunochemistry. Each sample was embed-
ded in paraffin and cut into 5-m sections.
Assessment of intimal hyperplasia. Four weeks after
the operation, vein grafts in both groups (n  7, respec-
tively) were harvested, and intimal hyperplasia of the vein
graft of both groups was assessed as described previously.12
In brief, each section harvested 4 weeks after implantation
was deparaffinized in a xylene/ethanol series and stained
with either hematoxylin and eosin or the elastica van Gie-
son method. Four sections were obtained from each vein
graft. The intimal hyperplasia was measured by MACSCOPE
(Mitani Co, Fukai, Japan) at eight randomly selected dif-
ferent views per sections. The average of eight values was
considered to represent the intimal hyperplasia of the sec-
tion, and the average of the four sections was considered to
represent those of the graft. The cross-sectional area of the
intimal hyperplasia was also calculated by MACSCOPE in
the samemanner. These values were then used for statistical
analysis.
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nuclear antigen. Two weeks after implantation, vein
grafts in both groups (n  7, respectively) were harvested.
For immunohistologic analysis, monoclonal mouse anti-
body against proliferative cell nuclear antigen (PCNA)
(clone PC 10, 1:200 dilution) (DAKO Cytomation Inc,
Carpenteria, Calif) was used as described in our previous
report.12 The formalin-fixed, paraffin-embedded tissue sec-
tions harvested 2 weeks after implantation were deparaf-
finized in a xylene/ethanol series and treated with 3%
hydrogen peroxidase for 10 minutes at room temperature
to inhibit endogenous peroxidase activity. To decrease
nonspecific binding, the slides were preincubated with nor-
mal horse serum for 30 minutes.
After washing with phosphate-buffered saline (PBS),
the sections were incubated with primary antibody for 60
minutes at room temperature. The sections were then
treated with the DAKO Envision  System, following the
manufacturer’s instructions. Briefly, peroxidase-labeled
polymer conjugated to goat antimouse immunoglobulins
was applied to the sections for 30 minutes at room tempera-
ture. After washing with PBS, liquid 3,3=-diaminobenzidine
(DAB) plus substrate-chromogen solution was applied to
the sections, which were incubated for 5 to 10 minutes.
Each section was then lightly counterstained with hematox-
ylin and brown-stained positive cells were counted.
To calculate the PCNA index, eight high-power fields
(400) per section were selected randomly and PCNA-
positive cells and total cells were counted in the neointima
in a blinded manner. The average of the eight values was
considered to represent the number of cells in one section,
and the average of the four sections was considered to
represent those of one vein graft. The number of positive
cells divided by the total number of cells of the vein graft
was defined as the PCNA index, as described in our previ-
ous report.12
Terminal deoxynucleotidyltransferase-mediateddUTP-
biotin nick end labeling assay. Two weeks after implan-
tation, vein grafts in both groups (n 7, respectively) were
harvested. To evaluate apoptotic activity, we used the ter-
minal deoxynucleotidyl transferase-mediated dUTP-biotin
nick end labeling (TUNEL) method to detect in situ
apoptosis. The assay was performed with a detection kit
(Takara Bio, Shiga, Japan) in accordance with the manu-
facturer’s instructions as well as a previous report.19 The
counterstaining was done lightly with hematoxylin. Eight
high power fields (400) per section were selected ran-
domly, and TUNEL-positive cells and total cells were
counted in the neointima in a blinded manner. Nonspecific
cytoplasmic staining without nuclear involvement was con-
sidered negative. The number of positive cells divided by
the total number of cells counted was defined as the
TUNEL index of the vein graft.
Experiment 2: In vitro cell-selective effect of
hydrophilic statin
Cell culture. Human umbilical vein endothelial cells
(HUVECs) and vascular smooth muscle cells (VSMCs)pooled from several donors were purchased from Cascade
Biologics, Inc (Portland, Ore) and grown in Humedia-EG,
(Cascade Biologics, Inc) according to the manufacturer’s
instructions as described previously.20 In all experiments,
the cells were used between passages five and six.
Observation of myosin binding subunit phosphor-
ylation and eNOS protein expression. Myosin binding
subunit (MBS) phosphorylation and Rho/ Rho-kinase ac-
tivity in HUVECs and VSMCs were examined. The cells
were seeded on 60-mm collagen type-1 coated dishes
(Iwaki, Tokyo, Japan) at a density of 8 105 cells per dish
and cultured overnight. The cells were then treated with 1
mol/L and 30 mol/L pravastatin for 24 hours and
harvested with 10% (wt/vol) trichloroacetic acid. The re-
sulting precipitates were subjected to immunoblotting with
antiphospho-MYPT-1 (Thr850) (Upstate, Waltham, Mass),
anti-MBS antibody,20 anti-RhoA (Cytoskeleton Inc, Den-
ver, Colo), anti-ROCK I (C-19) (Santa Cruz Biotechnol-
ogy, Inc, Santa Cruz, Calif), anti-ROCK II (C-20) (Santa
Cruz Biotechnology, Inc), and anti-eNOS/NOS type III
(BD Biosciences Inc, San Jose, Calif). The region contain-
ing MBS, ROCK I, ROCK II, RhoA, and eNOS was
visualized using ECL Western blotting system (Amersham
Biosciences, Piscataway, NJ). Quantitative evaluation of
phosphorylated MBS and eNOS was performed by densi-
tometric analysis using the ATTO Densitograph (ATTO,
Tokyo, Japan), as described previously.20
Statistical analysis. All values were expressed as the
mean SEM. The data were evaluated with Student’s t test
or compared by one-way analysis of variance. Differences
between groups were considered to be statistically signifi-
cant when the P value was  .05.
RESULTS
Experiment 1: In vivo effect of pravastatin on vein
graft intimal hyperplasia
All animals survived, and all vein grafts (n  28) were
patent until the time of harvest.
Suppression of intimal hyperplasia of the vein graft
by pravastatin. Intimal hyperplasia developed in both
groups (n  7, respectively), but the degree of intimal
thickness in the pravastatin group (39.5  3.5 m) was
significantly suppressed compared with the control group
(64.0  7.1 m) (P  .05) (Fig 1, A and B). These findings
showed the suppressive effect of pravastatin on the degree
of the intimal hyperplasia of vein grafts implanted in the
arterial circulation.
Plasma lipid profile levels after 4 weeks’ administra-
tion of pravastatin. After 4 weeks, there was no signifi-
cant change in plasma total cholesterol levels in the prava-
statin group (21.4  3.4 mg/dL) compared with the
control group (26.6  2.1 mg/dL), and no change in
triglyceride levels in the pravastatin group (21.4  3.4
mg/dL) compared with the control group (24.0  2.6
mg/dL) (Fig 2, A and B). There was a significant reduction
in plasma LDL levels in the pravastatin group (4.9  0.3
control.
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mg/dL) (P  .05) (Fig 2, C).
Suppression of cell proliferative activity by pravasta-
tin. The PCNA index was measured by using vein grafts
harvested 2 weeks after implantation (n  7, respectively).
The PCNA index of the neointimal lesion was significantly
lower in the pravastatin group (16.2%  .7%) compared
with the control group (24.5%  0.5%) (P  .05) (Fig 3, A
and B).
Cell apoptosis and vein graft intimal hyperplasia. To
confirm the relationship between cell apoptosis and the
inhibitory effect of pravastatin on intimal hyperplasia, a
TUNEL assay was performed with vein grafts harvested 2
weeks after implantation (n  7, respectively). TUNEL-
Fig 1. Effect of pravastatin on the development of intimal hyper-
plasia of the vein graft 4 weeks after operation. A, Microscopic
findings of the middle portion of an autologous vein graft from the
control group fed with normal rabbit chow and the pravastatin
group fed daily with special chow containing 10 mg/kg pravasta-
tin. Arrowheads indicate the internal elastic lamina (elastica van
Gieson staining; original magnification 400). B, Quantitative
analysis of intimal hyperplasia of vein grafts by random eight-point
measurement. The intimal thickness was significantly suppressed in
the pravastatin group (n  7) compared with the control group
(n  7). Results are expressed as the mean  SEM. *P  .05 vs
control.positive cells in the neointima of the vein graft were signif-Fig 2. Lipid profile after oral administration of pravastatin.
Plasma lipid profiles were measured after 4 weeks in the control
group (n  7) fed with normal rabbit chow and the pravastatin
group (n 7) fed daily with special chow containing 10 mg/kg of
pravastatin. A, Total cholesterol levels and (B) plasma triglyceride
levels in both groups showed no significant change. C, Plasma
low-density lipoprotein (LDL) levels were slightly decreased in the
pravastatin group, but the baseline LDL levels in both groups were
very low. Results are expressed as the mean  SEM. *P  .05 vs
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compared with the control group (7.1% 0.7%) (P .05)
(Fig 4, A and B).
Experiment 2: In vitro cell-selective effect of
pravastatin
MBS phosphorylation and Rho/ Rho-kinase activ-
ity inHUVECs andVSMCs. The expression levels of the
Rho-kinase isoforms, RhoA, ROCK I, and ROCK II, were
measured in HUVECs and VSMCs using Western blot
analysis (n  6, respectively). We also measured MBS, the
target protein of Rho-kinase, and phospho-MBS, the inac-
tive form of MBS (n  6, respectively). Both types of cells
Fig 3. Effects of pravastatin on proliferative activity of the vein
graft neointima. The proliferative cell nuclear antigen (PCNA)
index was measured by using vein grafts harvested 2 weeks after
implantation. Counterstaining was done lightly with hematoxylin.
A,Microscopic findings with PCNA staining of the middle portion
of an autologous vein graft from the control group and the
pravastatin group. Arrowheads show PCNA-positive cells in the
neointima (original magnification400). B,Quantitative analysis
of the frequency of PCNA-positive cells. The PCNA index, the
number of PCNA-positive cells divided by the number of total
cells, was significantly suppressed in the pravastatin-treated group
(n  7) compared with the control group (n  7). Results are
expressed as the mean  SEM. *P  .05 vs control.were treated with 1 mol/L and 30 mol/L pravastatin orno pravastatin (control) for 24 hours. Phosphorylation of
MBS in HUVECs was significantly suppressed by both
concentrations of pravastatin compared with control (Fig
5), but expression levels of RhoA, ROCK I, and ROCK II
were not affected (data not shown). In contrast, phosphor-
ylation of MBS in VSMCs was not suppressed by pravasta-
tin (Fig 6).
Effects of pravastatin on eNOS expression and
phosphorylation in HUVECs. HUVECs were treated
with 1 mol/L and 30 mol/L pravastatin or no pravasta-
tin (control) for 24 hours, and protein levels of eNOS were
examined (n 6, respectively). The eNOS protein levels in
the HUVECs were significantly higher even with 1
Fig 4. Effects of pravastatin on cell apoptotic activity in the vein
graft neointima. The terminal deoxynucleotidyl transferase-mediated
dUTP-biotin nick end labeling (TUNEL) method was done by
using vein grafts harvested 2 weeks after implantation. Counter-
staining was done lightly with hematoxylin. A, Microscopic find-
ings of the middle portion of vein grafts from the control group
and the pravastatin group.Arrowheads showTUNEL-positive cells
in the neointima (original magnification 400). B, Quantitative
analysis of the frequency of TUNEL-positive cells. The TUNEL
index, the number of TUNEL-positive cells divided by the number
of total cells, was significantly increased in the pravastatin group
(n  7) compared with the control group (n  7). Results are
expressed as the mean  SEM. *P  .05 vs control.mol/L of pravastatin compared with the control (Fig 5).
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We have demonstrated that the hydrophilic statin prav-
astatin inhibits vein graft intimal hyperplasia through sup-
pression of the proliferative activity and acceleration of cell
apoptosis in the neointima in the normocholesterolemic
rabbit. We also found that pravastatin suppressed Rho-
kinase activity in HUVECs, but not in VSMCs, and in-
creased the expression levels of eNOS in HUVECs. To our
knowledge, this is the first study reporting the endothelial
cell-tropic suppression of Rho-kinase activity and a suppres-
sive effect of hydrophilic statin treatment on vein graft
intimal hyperplasia.
Vein graft intimal hyperplasia. Intimal thickening of
autologous vein grafts is the major cause of late graft
failure.2,3 Implantation of a vein graft in the arterial circu-
Fig 5. To evaluate the effect of pravastatin on Rho-kinase activity,
myosin-binding subunit phosphorylation (MBS-P) and endothe-
lial nitric oxide synthase (eNOS) expression were measured in
human umbilical vein endothelial cells (HUVECs) (n  6) by
usingWestern blot analysis. HUVECswere treated with 1mol/L
pravastatin or no pravastatin (control) for 24 hours. The total
amount of eNOS was increased compared with the control cells,
and phosphorylation level of MBS was decreased. The total
amount of MBS was not affected by pravastatin. Results are ex-
pressed as the mean  SEM. *P  .05 vs control, **P  .01 vs
control.lation induces various changes that may lead to intimalhyperplasia, such as increased sheer stress, loss of endothe-
lial cells, migration and invasion of inflammatory cells, and
migration and proliferation of VSMCs.21,22 We previously
reported that pronounced intimal thickening of a vein graft
was associated with impairment of endothelial responses
and cell proliferative activity of the neointima.11,23 Various
treatments were examined to reduce intimal hyperplasia of
vein grafts,12,24 but standard clinical treatment has not yet
been established.
We report here, for the first time, the inhibitory effect
of pravastatin on the development of vein graft intimal
hyperplasia in vivo. Our demonstrated suppression of cell
proliferative activity and acceleration of cell apoptosis in the
neointima of vein grafts by pravastatin confirms previous
findings.12
Statins and Rho-kinase. Statins are among the most
widely prescribed drugs, and several large clinical trials have
demonstrated the benefits of cholesterol lowering with
Fig 6. To evaluate the effect of pravastatin on Rho-kinase activity,
myosin-binding subunit phosphorylation (MBS-P) was measured
in vascular smoothmuscle cells (VSMCs) (n 6) by usingWestern
blot analysis. VSMCs were treated with 1 M and 30 M prava-
statin or no pravastatin (control) for 24 hours. Phosphorylation
level of MBS in VSMCs was not suppressed by the pravastatin
treatment at 1 mol/L and 30 mol/L. Results are expressed as
the mean  SEM.these agents in the primary and secondary prevention of
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showed that statins provided beneficial effects independent
of lipid-lowering effects,6,7 so called pleiotropic effects.25
These effects reflect the ability of statins to reduce the
formation of the important isoprenoid intermediates farne-
syl pyrophosphate and geranylgeranylpyrophosphate.4,10,26
Blockade of geranylgeranylation inhibits the small guanosine
triphosphatase (GTPase) protein, Rho, and Rho-kinase/
ROK/ROCK activity, the target protein of Rho.26 The
Rho/Rho-kinase pathway controls multiple cell functions
such as adhesion, proliferation, migration, and the calcium
sensitivity of the contractile proteins.26,27 Previous studies
also revealed that Rho-kinase inactivates myosin phospha-
tase through phosphorylation of MBS at thr-850, resulting
in phosphorylation of myosin light chain and contraction of
VSMCs,28 and that phosphorylation level of MBS at thr-
850 correlates with Rho-kinase activity specifically.
Recent studies revealed that inhibition of Rho-kinase
activity protects endothelial cells. Some studies demon-
strated that inhibition of myosin light chain stabilizes
eNOS messenger RNA (mRNA) through suppression of
actin stress fibers, which negatively regulates eNOS mRNA
and increases eNOS protein expression.29 Another study
showed that active Rho or Rho-kinase decreased eNOS
expression, and negative Rho or Rho-kinase abrogated
downregulation of eNOS.30 In addition, long-term inhibi-
tion of Rho-kinase reversed endothelium-dependent relax-
ation and regressed arterial intimal hyperplasia.14
Our study demonstrates, for the first time, the suppres-
sive effect of therapeutic concentrations of pravastatin 31 on
Rho-kinase activity confirmed by MBS phosphorylation in
HUVECs. Interestingly, the tendency of this inhibition was
recognized inHUVECs at 1 mol/L of pravastatin but did
not occur in VSMCs at concentrations of 1 mol/L or
30 mol/L.
Statins and eNOS. Endothelial-derived NO has been
recognized as an anti-inflammatory and anti-arteriosclerotic
molecule.32,33 Inhibition of Rho-kinase activity by statins
accelerates eNOS protein expression as described above. 9,34
Our previous studies demonstrated a relationship between
reduced production of NO in experimental autologous
vein grafts 11 and intimal hyperplasia. Furthermore, intimal
hyperplasia of vein grafts was suppressed by activation of
NO production through gene transfer of eNOS12 and oral
administration of the NO precursor L-arginine.13 In this
study, we demonstrated the tendency of increasing eNOS
expression at 1 m and 30 m pravastatin in HUVECs.
The efficacy of hydrophilic statin. In the injured
artery model, pravastatin did not suppress intimal hyperpla-
sia in contrast to other statins like simvastatin and atrovas-
tatin.15,16 However, it is still controversial which statins—
lipophilic or hydrophilic—have more clinical benefits,
because many clinical trials suggest that hydrophilic statins
have vasculo-protective effects similar to those of lipophilic
statins.5,6 Furthermore, some studies reported that hydro-
philic statins were more effective in stabilizing plaques
because thick fibromuscular caps, which consist of a large
number of smooth muscle cells and collagen fibers, arethought to contribute to plaque stabilization.35,36 In the
present study, we showed the suppressive effect of a hydro-
philic statin on intimal hyperplasia of vein grafts in vivo. We
also demonstrated the suppression of Rho-kinase activity
confirmed by MBS phosphorylation in HUVECs, but not
in VSMCs, and the tendency of acceleration of eNOS in
HUVECs at therapeutic pravastatin concentrations 37,38 in
vitro.
Drug concentration and interaction. In the previous
reports, the oral administration of pravastatin in hyperlip-
idemic rabbit decreased serum cholesterol at daily doses
10mg/kg, almost the same dosage as in this study, and at
doses5 mg/day in primary hyperlipidemic patients. This
indicates that the estimated therapeutic dose of pravastatin
to reduce intimal hyperplasia was almost the same as the
clinically approved doses in hypercholesterolemic pa-
tients.39,40
Because many drugs, including anticoagulants, antibi-
otics, antihypertensive and some lipophilic statins, are me-
tabolized by CYP enzymes,38 drug interactions between
statins and other agents may be very important. For exam-
ple, some anticoagulants were indispensable to postopera-
tive patients who received vein bypass grafting of coronary
or peripheral arteries, and important drug interactions oc-
curred between statins and these agents. Hydrophilic
statins like pravastatin are thought to have fewer drug
interactions compared with other agents that are metabo-
lized by CYP enzymes17 and thus have fewer restrictions for
use in postoperative patients.
CONCLUSION
Our present study clearly demonstrates the suppression
of development of intimal hyperplasia of the vein graft
through inhibition of cell proliferative activity and acceler-
ation of cell apoptosis in vivo. In addition, we demonstrate
for the first time that a hydrophilic statin showed endothe-
lial cell-tropic benefits both through inhibition of Rho-
kinase activity and acceleration of eNOS expression. This
novel finding facilitates the clinical use of hydrophilic
statins in postoperative patients to prevent intimal hyper-
plasia of the vein graft after vein bypass grafting.
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